Thalassaemia: vizsgálatok itt: Kína
28 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseTaking peopleGrowth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
- Where
- Tianjin
- Életkor
- 3 év to 14 év
- People
- 100
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05991336 - No phaseNot yet taking people in KínaGene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
- Where
- Shenzhen
- Életkor
- 4 év to 70 év
- People
- 20
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03351829 - 1/2. fázisTaking peopleβ-Thalassemia Treatment With KL003 Cell Injection
- Where
- Shanghai, Tianjin
- Életkor
- 3 év to 35 év
- People
- 41
- Run by
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
See details and how to joinNCT06280378 - No phaseTaking peopleA Long-term Follow-up Study in Participants Who Received CS-101
- Where
- Shanghai
- Életkor
- 3 év to 17 év
- People
- 5
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT06479616 - No phaseTaking peopleLow-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
- Where
- Haikou
- Életkor
- 3 év to 17 év
- People
- 30
- Run by
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07725263 - No phaseTaking peopleLong-term Follow-up Study of BRL-101 for TDT
- Where
- Changsha, Guangxi, Guangzhou, Nanning, Shenzhen, Tianjin
- Életkor
- 3 év to 35 év
- People
- 45
- Run by
- Bioray Laboratories
See details and how to joinNCT06298630 - 2. fázisTaking peopleStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Where
- Chengdu, Guangzhou, Nanning, Shenzhen
- Életkor
- 6 év to 17 év
- People
- 99 worldwide
- Run by
- Celgene
See details and how to joinNCT04143724 · EU 2022-502499-22-00 - 3. fázisTaking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin
- Életkor
- 18 év and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Korai 1. fázisCsak meghívásosCS-101 in Patients With β-thalassemia
- Where
- Nanning
- Életkor
- 6 év to 35 év
- People
- 10
- Run by
- CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06328764 - 2. fázisNot yet taking people in KínaA Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)
- Where
- Chengdu, Foshan, Guangzhou, Haikou, Liuzhou, Maoming, Nanning
- Életkor
- 18 év and over
- People
- 30
- Run by
- ScinnoHub Pharmaceutical Co., Ltd.
See details and how to joinNCT07579949 - 2. fázisNot yet taking people in KínaA Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- Where
- Nanning, Shanghai
- Életkor
- 12 év to 35 év
- People
- 20
- Run by
- CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT07489196 - 2. fázisTaking peopleA Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
- Where
- Guangzhou, Haikou, Liuzhou, Maoming, Nanning
- Életkor
- 18 év to 65 év
- People
- 64
- Run by
- Kind Pharmaceuticals LLC
See details and how to joinNCT06302491 - No phaseCsak meghívásosA Long-term Follow-up Study in Participants Who Received CS-101
- Where
- Nanning
- Életkor
- 6 év to 35 év
- People
- 5
- Run by
- CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06685536 - No phaseCsak meghívásosA Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
- Where
- Nanning
- Életkor
- 12 év to 35 év
- People
- 8
- Run by
- CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06717932 - 2. fázisTaking peopleEvaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
- Where
- Baise City, Kunming, Liuzhou, Naning, Shenzhen, Yulin
- Életkor
- 18 év to 75 év
- People
- 78
- Run by
- Rongrong Liu
See details and how to joinNCT07338344 - Korai 1. fázisNot yet taking people in KínaYOLT-204 in Patients With Hemoglobinopathies
- Where
- Guangzhou
- Életkor
- 3 év to 17 év
- People
- 18
- Run by
- Guangzhou Women and Children's Medical Center
See details and how to joinNCT07190001 - No phaseTaking peopleA Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
- Where
- Kunming
- Életkor
- 7 év to 12 év
- People
- 5
- Run by
- Hu Peng
See details and how to joinNCT06743477 - 1. fázisTaking peopleA Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- Where
- Haikou, Nanning
- Életkor
- 18 év to 65 év
- People
- 40
- Run by
- Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT06772766 - No phaseTaking peopleClinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
- Where
- Guangzhou
- Életkor
- 7 év to 10 év
- People
- 3
- Run by
- Guangzhou Women and Children's Medical Center
See details and how to joinNCT06734520 - Korai 1. fázisTaking peopleSafety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
- Where
- Shenzhen
- Életkor
- 8 év to 16 év
- People
- 10
- Run by
- Shenzhen Hemogen
See details and how to joinNCT05745532 - Korai 1. fázisTaking peoplethe Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
- Where
- Nanning
- Életkor
- 12 év to 35 év
- People
- 3
- Run by
- Shenzhen Hemogen
See details and how to joinNCT05851105 - Korai 1. fázisTaking peoplethe Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
- Where
- Shenzhen
- Életkor
- 18 év to 35 év
- People
- 3
- Run by
- Shenzhen Hemogen
See details and how to joinNCT05864170 - 2. fázisTaking peopleEvaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
- Where
- Haikou, Liuzhou, Maoming, Nanning, Yulin
- Életkor
- 3 év to 20 év
- People
- 396
- Run by
- Rongrong Liu
See details and how to joinNCT06657391 - 1. fázisTaking peopleEvaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
- Where
- Guangxi, Shenzhen
- Életkor
- 6 év to 35 év
- People
- 8
- Run by
- Shenzhen Hemogen
See details and how to joinNCT06655662 - 1. fázisTaking peopleA Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Where
- Guangzhou, Nanning, Shanghai
- Életkor
- 3 év to 35 év
- People
- 9
- Run by
- Shanghai BDgene Co., Ltd.
See details and how to joinNCT06465550